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Dasatinib is a common anticancer drug used in the treatment of leukemia. Several side effects have been reported,
the most common being myelosuppression, diarrhea, edema, and nausea. Three papers have been published
reporting hepatic side effects of dasatinib treatment. A rare side effect of dasatinib treatment is reactivation of
latent cytomegalovirus (CMV) infection. Never before has dasatinib therapy shown to be the cause of CMV
hepatitis in an immunocompetent patient. We present a case of an immunocompetent patient who was treated
with the standard dose of dasatinib therapy and subsequently developed CMV hepatitis. Well-known side effects
of dasatinib therapy are understood and documented; unknown adverse drug reactions can occur and should be
monitored for. This is a significant finding given the high rate of CMV seropositivity in the general population.
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Dasatinib is a common anticancer drug used in the treatment of
leukemia, particularly Chronic Myelogenous Leukemia (CML). It is a
relatively new tyrosine kinase inhibitor approved in 2006. Several side
effects have been reported, the most common being myelosuppres-
sion, diarrhea, edema, and nausea, with diarrhea seen in 30% of
patients and nausea reported in 20%. The first adverse hepatic effect
of dasatinib therapy was reported in the literature in 2008. Since then,
only three papers have been published that report hepatic side effects
of dasatinib treatment. Another rare side effect of dasatinib treatment
is reactivation of latent cytomegalovirus (CMV) infection in
immunocompromised hosts. CMV hepatitis is often seen in the
immunocompromised population; however, dasatinib has not yet
been reported as a causative agent of CMV hepatitis. CMV
reactivation has been documented as a side effect of dasatinib therapy
in two cases. Neither of these cases reported hepatic involvement.
Both reported cases of CMV reactivation resulted in hemorrhagic
colitis. Never before has dasatinib therapy been reported to be the
cause of CMV hepatitis in an immunocompetent patient.
Case Report
A 42-year-old woman with a 5-year history of CML who was treated
with dasatinib 100 mg q24h presented with a 12-day history of upper
respiratory symptoms. She was seen in the emergency department and
treated with a 5-day course of Tamiflu which failed to relieve her
symptoms. The patient reported intermittent fevers accompanied bychills and body aches for which she took Motrin PRN. The patient
stated that her children were sick at home with symptoms of an upper
respiratory illness. She denied any cough or nasal congestion, sore
throat, urinary symptoms, and abdominal pain. On initial examina-
tion, the lungs were clear to auscultation bilaterally. No lymph nodes
were palpable on exam. S1 and S2 heart sounds were heard clearly
with no murmurs. Abdominal examination revealed a soft, nontender
abdomen with no guarding or rigidity in all quadrants. No rashes,
cuts, bruises, or edema was noted on any exposed skin. The patient
denied any muscle or joint pain. The patient had a history of diabetes
mellitus and had a cholecystectomy 4 years before admission. On
admission, she presented with a fever of 100.9°F. Her Point Of Care
(POC) glucose was 161, white blood cell count was 4.0 K/μl,
hemoglobinwas 10.9 g/dl, hematocrit was 33.3 l, and platelet count was
472 K/μl. Aspartate aminotransferase was 200 U/l, alanine amino-
transferase was 134 of U/l, alkaline phosphatase was 287 U/l, lactate
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albumin of 3.2 g/dl. Anion gap was 11.3 mM, estimated glomerular
filtration rate was N90.00 ml/min, magnesium was 1.9 mg/dl, mean
corpuscular hemoglobin was 28.1 pg, mean corpuscular hemoglobin
concentration was 32.0 g/dl, mean platelet volume was 7.5 fl,
international ratio was 1.20, prothrombin time was 12.5 seconds,
activated partial thromboplastin timewas 22.8 seconds, red blood count
was 3.20 m/μl, red cell distribution width was 20.4%, and mean
corpuscular volume was 87.3 fl. Patient was started on levofloxacin for
possible urinary tract infection or pneumonia given the unclear etiology
of her unremitting fever. She remained on the drug for 5 days until it
was discontinued despite the cause of the fever remaining unclear.
Two-dimensional echocardiogram, and chest and lateral spine X-ray
computed tomography of the chest, abdomen, and pelvis showed no
significant findings. Given her episodic fever and elevated liver function
tests, cultures were drawn for malaria and CMV, along with a malarial
smear, fungal culture, Epstein-Barr virus (EBV), immunoglobulin (Ig)
M, and Clostridium difficile. Results of malarial smear, fungal culture,
EBV IgM, and C. difficile all were negative. CMV IgG showed positive
IgG levels of CMV infection at 4.60 with a reference range of b0.91
being negative for infection and N1.10 being a positive result. CMV
IgM for our patient showed a level of 4.0 with N1.1 being a positive
result. Given the positive CMV IgM and IgG titers in conjunction with
the elevation in liver function tests, a diagnosis was made of CMV
hepatitis. The patient was subsequently started on gangciclovir at 5 mg/
kg q12h IV for 14 days for induction therapy. Desatinib therapy was
stopped during the treatment for CMV hepatitis. Ophthalmology
examination was performed and showed a retinal hemorrhage of left eye
not consistent with CMV retinitis, with no diabetic retinopathy. The
patient was monitored until liver function tests returned to normal and
her fever subsided. Dasatanib therapy was restarted, and a Peripherally
Inserted Central Catheter (PICC) line was placed following the
remission of her symptoms. The patient was subsequently discharged
with gangciclovir and was given an outpatient appointment to monitor
subsequent CMV levels.
Discussion
CMV is a member of the herpesvirdae family. It is a double-stranded
DNA virus that often affects immunosuppressed patients [1]. Active
infection with CMV virus is rarely seen in immunocompetent hosts.
Rather, it is usually the result of a reactivation of a latent infection
caused by immunosuppression. For CMV to result in end-organ
damage, CD4 count of less than 50 is expected, as often seen in AIDS
patients [2]. The severity of CMV infection is positively correlated to
viral load, with the highest viral load being responsible for end-organ
damage. In particular cases, such as immunocompetent hosts and
pregnant woman, CMV infection often mimics the signs and
symptoms of an infection with EBV. The second most common
presenting signs in immunocompromised host are central nervous
system manifestations mimicking the presentation of influenza.
Dasatinib is a tyrosine kinase inhibitor that is metabolized by
CYP3A4. In addition to being metabolized by this cytokine, it also
inhibits this same enzyme. The exact mechanism of the adverse effects
of dasatinib therapy is unknown. It is postulated that the side effects
may be the result of tyrosine kinase inhibitory effects in unintended
locations [3]. There may also be specific inhibitor effects on PDGF,
c-KIT, BCR-ABL, and SRC-family kinases. Induction of the
SRC-family kinases may specifically inhibit T-cell andNK-cell function
leading to reactivation of a latent infection in an immunocompetenthost [3,4]. Dasatinib has been reported to inhibit platelet aggregation in
85% of patients being treated for CML. Therefore, bleeding is an
expected complication [5,6]. There have been reported cases of CMV
hemorrhagic colitis secondary to dasatinib treatment and even
documented cases of pulmonary damage [2,7–9]. To date, there is
only one documented case of dasatinib-induced hepatitis in which the
patient had no evidence of an active CMV infection [10]. Detection of
the CMV virus in host patients can be determined in several ways. The
more popular methods are PCR, viral antigen, viral culture, and
immunohistochemical staining. In our patient, the CMV virus was
detected using levels of serum IgM and IgG antibodies. In the event of
an acute flare-up, CMV infection can be detected by evaluating the
concentration of IgG anti-CMV antibodies. Several imatinib-related
cases of hepatic damage have been reported in the literature [5].
Imatinib-induced hepatic damage has been reported as soon as 2
months after initiation of treatment and as late as 2 years after initial
treatment. The timeline of this adverse effect is not yet understood for
dasatinib. An appropriate timeline for this side effect could provide a
better guide to hepatic monitoring in patients being treated with
dasatinib. Dasatinib therapy is aimed at creating a complete cytogenetic
response within 12 months [10]. This response in patients correlates to
a good prognosis and is currently the best hope for halting disease
progression. This positive correlation between dasatinib treatment and
disease regression occurs at the standard dose of 100mg once daily. Our
patient was on this regimen. Serious side effects noted at this dosage are
of particular interest. This treatment modality is still fairly new, which
makes awareness of rare side effects essential. Additional importance of
this case lies in the possible use of imatinib as an alternative for
treatment in patients with hepatic damage or increased risk factors for
hepatitis. According to the CDC, 50% to 80% of US adults will be
infected with CMV by the time they reach 40 years of age [1]. Given
this high rate of infection with CMV, the dangers of reactivation of a
latent infection as a result of drug therapy should be noted. This is of
particular interest given the possibility of CMV-induced end-organ
damage such as seen in our patient. We suggest that CML patients
being treated with dasatinib therapy undergo testing for CMV infection
before initiation of therapy.Once dasatinib therapy has been initiated in
a CMV-positive patient, routine testing of CMV antibodies may help
guide the course of treatment. In the event of a CMV reactivation, an
alternative treatment may be a safer option to avoid complications. If
dasatinib does induce CMVhepatitis as shown in our patient, treatment
should be guided based on CMV seropositivity. In a CMV-positive
patient, imatinib may be a safer alternative to dasatinib [11].
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